Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoflurophate (diisopropyl fluorophosphate) is an organophosphorus compound and irreversible cholinesterase inhibitor used primarily as ocular drops in the treatment of chronic open-angle glaucoma and other eye conditions such as accommodative esotropia. It acts by covalently binding to acetylcholinesterase and cholinesterase enzymes inactivating them and preventing the breakdown of acetylcholine. This leads to increased levels of acetylcholine at cholinergic synapses resulting in parasympathomimetic effects such as miosis (pupil constriction) and reduced intraocular pressure. Isoflurophate has also been used before or after certain eye surgeries to manage intraoperative or postoperative increases in intraocular pressure. Its use is limited due to its high toxicity; exposure can cause severe systemic symptoms if not handled properly[1][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isoflurophate.